The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction
Russian Journal of Cardiology, cilt.27, sa.9, ss.83-91, 2022 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 27 Sayı: 9
- Basım Tarihi: 2022
- Doi Numarası: 10.15829/1560-4071-2022-5021
- Dergi Adı: Russian Journal of Cardiology
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
- Sayfa Sayıları: ss.83-91
- Anahtar Kelimeler: ticagrelor, TIMI flow grade, TIMI frame count
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim. We aimed to compare post-interventional angiographic outcomes of ticagrelor versus clopidogrel according to glycosylated hemoglobin (HbA1c) levels in patients with ST-elevation myocardial infarction. Material and methods. The study included a total of 532 patients, with 334 receiving ticagrelor (62,8%) and 198 clopidogrel (37,2%). Diabetic status of the patients was assessed with HbA1c. TIMI flow grade and TIMI frame count were calculated and compared between two groups. Results. TIMI flow grade 3 was higher and TFC was lower after percutaneous coronary intervention of the infarct-related artery in patients treated with ticagrelor compared to clopidogrel (89,2% vs. 73,7%; p<0,001, 20 vs. 24; p<0,001). There was a positive correlation between the increases in HbA1c and TFC levels in the whole group (r=0,225; p=0,004). In subgroup analysis, higher HbA1c levels did not affect TFC in patients using ticagrelor (r=-0,060; p=0,326 for patients with no-reflow, r=-0,133; p=0,321 for patients with TIMI-3 flow). While level of HbA1c did not affect TFC in patients with TIMI-3 flow, the presence of post-procedural no-reflow caused worsening of TFC in patients using clopidogrel as HbA1c levels increased (r=0,374; p=0,005). Conclusion. Ticagrelor was found to be better in terms of angiographic parameters regardless of diabetes.